In addition, results of a recent phase 2 study showed another c-KIT/FLT3 inhibitor dovitinib, also known as TKI-258, did not appear to have improved activity over sorafenib in patients with advanced HCC 41, our data suggested that future trials can be designed to test the therapeutic efficacy of a combined treatment with sorafenib and imatinib or dovitinib in patients with high expression levels of OCT4wt and c-KIT. This evidence concerns the gene KIT and hepatocellular carcinoma.